- Transcenta has agreed to sell its Hangzhou CDMO manufacturing assets to WuXi Biologics for RMB 190.0 million (approximately $26.2 million).
- The company will retain its proprietary bioprocessing technologies and use the proceeds to support pipeline development, including advancing osemitamab into a global Phase III trial.
Transcenta Holding Limited has entered into an agreement to sell its Hangzhou CDMO manufacturing assets to WuXi Biologics for RMB 190.0 million (approximately $26.2 million). The agreement, signed on August 6, 2026, covers the company’s GMP manufacturing plant in Hangzhou, including land use rights, buildings, manufacturing equipment, business contracts, and designated employees. The transaction is subject to shareholder approval and is expected to close by December 31, 2026.
The asset sale excludes Transcenta’s intellectual property, including its Highly Intensified Continuous Bioprocessing (HiCB) platform and ExcelPro CHO cell culture media. Following the transaction, the company will shift away from physical manufacturing to focus on its drug development pipeline and licensing of its proprietary bioprocessing technologies. It also plans to use third-party contract manufacturing providers to support future manufacturing requirements while retaining selected in-house chemistry, manufacturing, and controls capabilities.
According to Transcenta, the transaction will provide near-term cash without equity dilution and is expected to strengthen the company’s financial position for fiscal 2026. The company also reported reductions in labor and operating expenses during the first half of 2026 as part of efforts to optimize its manufacturing cost structure.
Proceeds from the sale will be directed toward pipeline development, including advancing lead candidate osemitamab (TST001), an anti-Claudin18.2 antibody, into a global Phase III clinical trial for gastric and gastroesophageal junction cancer. Transcenta will also continue licensing its HiCB platform, which remains outside the scope of the asset sale.
